Role of arterial compliance in the physiopharmacological approach to human hypertension
- PMID: 1381785
Role of arterial compliance in the physiopharmacological approach to human hypertension
Abstract
Arterial compliance in humans is generally measured by modeling analysis of pulse tracing or of pulse wave propagation in the arterial tree. It is decreased in hypertension in part because elevation of blood pressure stiffens the arteries by stretching the rigid collagen fibres of their walls. Using a modeling evaluation of the compliance-pressure relationship in large arteries, it is possible to correct compliance from the mechanical effect (passive effect) due to pressure elevation. This makes it possible to show that, at the same pressure as in normal controls, hypertensive patients maintain decreased arterial compliance. This finding suggests that functional and/or structural changes other than pressure-mediated stretching of arteries (active effect) contribute toward reducing arterial compliance. Thus, the response of compliance to antihypertensive drugs must be studied by differentiating between passive and active effects. The diameter and compliance-pressure relationship in arteries allow differentiation of a passive arterial effect due to the pressure-lowering action of the drug, and an active pharmacological effect calculated at the same pressure before and after drug administration. Four drugs--ketanserin, urapidil, nitrendipine, and nicardipine (acute administration)--are given as examples. No active or passive compliance changes are observed with urapidil and ketanserin. In contrast, an active increase in compliance is observed in isobaric conditions with calcium antagonists, together with large-artery dilation due to a potent smooth muscle-relaxing effect. This active increase in compliance is potentiated by a passive increase due to the pressure-lowering effect that reduces the mechanical stretch exerted by blood pressure on arterial bioelastomers. Finally, an optimum increase in arterial compliance is achieved by drugs that vasodilate large arteries by smooth muscle relaxation and concomitantly decrease blood pressure. This may be of importance because low compliance has adverse effects on the cardiovascular system by contributing to the pathogenesis of systolic hypertension and left ventricular hypertrophy. Loss of arterial compliance may also be an early marker of atherosclerosis.
Similar articles
-
Physiopharmacological approach to mechanical factors of hypertension in the atherosclerotic process.J Hum Hypertens. 1991 Aug;5 Suppl 1:15-21. J Hum Hypertens. 1991. PMID: 1941880 Review.
-
Differential responses of the heart and vasculature to chronic blood pressure reduction in essential hypertension.Clin Pharmacol Ther. 1998 Jul;64(1):96-105. doi: 10.1016/S0009-9236(98)90027-3. Clin Pharmacol Ther. 1998. PMID: 9695724 Clinical Trial.
-
Hypertension and the arterial system: clinical and therapeutic aspects.J Hypertens Suppl. 1990 Dec;8(7):S113-9. J Hypertens Suppl. 1990. PMID: 2095379 Review.
-
Arterial compliance in hypertension.J Hum Hypertens. 1989 Jun;3 Suppl 1:53-6. J Hum Hypertens. 1989. PMID: 2674442 Review.
-
[Drugs and arterial stiffness in hypertensive patients].Drugs. 2003;63 Spec No 1:1-8. Drugs. 2003. PMID: 12708878 Review. French.
Cited by
-
Sonic vibrational analysis provides continuous measurement of arterial properties.J Clin Monit Comput. 2000;16(7):501-8. doi: 10.1023/a:1011457409522. J Clin Monit Comput. 2000. PMID: 12580209 Clinical Trial.
-
Decreased elastin in vessel walls puts the pressure on.J Clin Invest. 2003 Nov;112(9):1308-10. doi: 10.1172/JCI20226. J Clin Invest. 2003. PMID: 14597755 Free PMC article.
-
Relationship between proxies for Type II fiber type and resting blood pressure in Division I American Football Athletes.Int J Health Sci (Qassim). 2017 Apr-Jun;11(2):16-20. Int J Health Sci (Qassim). 2017. PMID: 28539858 Free PMC article.
-
Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta.Cardiovasc Drugs Ther. 1996 Mar;10(1):49-57. doi: 10.1007/BF00051130. Cardiovasc Drugs Ther. 1996. PMID: 8723170 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical